Insider at Lyra (NASDAQ: LYRA) files to sell 1,895 shares

Rhea-AI Filing Summary

Lyra Therapeutics insider plans a modest stock sale under Rule 144. A person for whose account the securities are to be sold, identified elsewhere as Maria Palasis, filed to sell 1895 shares of Lyra common stock on or about 01/27/2026 through Fidelity Brokerage Services LLC on the NASDAQ market. The aggregate market value of the planned sale is 3248.03, and the filing notes that 1774882 common shares are outstanding.

The 1895 shares to be sold were acquired on 01/12/2026 via restricted stock vesting from the issuer as compensation, with the same date listed for payment. The filer also reports that Maria Palasis sold 1702 Lyra common shares on 01/06/2026 for gross proceeds of 5725.36 during the past three months. By signing, the seller represents they are not aware of undisclosed material adverse information about Lyra’s operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	1895	3248.03	1774882	01/27/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/12/2026	Restricted Stock Vesting	Issuer			1895	01/12/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Maria Palasis 480 Arsenal Way Watertown MA 02472	Common	01/06/2026	1702	5725.36

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for LYRA disclose?

The Form 144 for Lyra Therapeutics (LYRA) discloses a planned sale of 1895 shares of Lyra common stock on or about 01/27/2026 on the NASDAQ market through Fidelity Brokerage Services LLC, with an aggregate market value of 3248.03.

Who is the insider associated with the recent LYRA Form 144?

The filing identifies Maria Palasis at an address in Watertown, MA as a seller of Lyra common stock in the past three months, including a sale of 1702 shares on 01/06/2026 for gross proceeds of 5725.36. The person for whose account the new 1895 shares are to be sold is linked to this information in the filing.

How many LYRA shares are being sold under this Form 144 and what is their value?

The notice covers a planned sale of 1895 shares of Lyra common stock with an aggregate market value of 3248.03, to be sold on NASDAQ through Fidelity Brokerage Services LLC.

How were the LYRA shares in this Form 144 acquired?

The 1895 Lyra common shares covered by the notice were acquired on 01/12/2026 via restricted stock vesting from the issuer, described as compensation, with the same date listed for payment.

What prior LYRA stock sales does the Form 144 mention?

The filing reports that Maria Palasis sold 1702 shares of Lyra common stock on 01/06/2026, generating 5725.36 in gross proceeds, as part of sales during the past three months.

How many LYRA shares are outstanding according to the Form 144?

The Form 144 states that 1774882 shares of Lyra common stock are outstanding, providing context for the relative size of the 1895-share planned sale.

Does the LYRA Form 144 include any representation about undisclosed information?

Yes. By signing the notice, the person for whose account the securities are to be sold represents that they do not know any material adverse information about Lyra’s current or prospective operations that has not been publicly disclosed.